<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-695X</journal-id>
<journal-title><![CDATA[Revista Clínica de Medicina de Familia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Clin Med Fam]]></abbrev-journal-title>
<issn>1699-695X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Medicina de Familia y Comunitaria]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-695X2022000100012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El síndrome de Eaton Lambert: una presentación clínica inusual que suele preceder al diagnóstico oncológico]]></article-title>
<article-title xml:lang="en"><![CDATA[Eaton lambert syndrome: a rare clinical presentation that usually precedes oncological diagnosis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Solana López]]></surname>
<given-names><![CDATA[Irene]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Izquierdo Martínez]]></surname>
<given-names><![CDATA[Aida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Losada Vila]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario de Fuenlabrada  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario de Fuenlabrada  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario de Fuenlabrada  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>15</volume>
<numero>1</numero>
<fpage>60</fpage>
<lpage>62</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-695X2022000100012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-695X2022000100012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-695X2022000100012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El síndrome de Eaton Lambert es un trastorno de tipo autoinmune que afecta a la unión neuromuscular. Cursa con debilidad muscular proximal y simétrica y en el 60% de los casos se asocia a una neoplasia subyacente. Dado que esta debilidad es de inicio insidioso, los pacientes suelen consultar inicialmente a su especialista de Medicina Familiar y Comunitaria. Reconocer esta entidad es fundamental para el diagnóstico precoz de la enfermedad oncológica ya que habitualmente precede en meses a los síntomas locales derivados de la enfermedad tumoral. El médico o médica de Atención Primaria tiene un papel fundamental en el adelanto diagnóstico y debe realizar una derivación precoz al medio hospitalario para completar el estudio. Presentamos un caso clínico de síndrome de Eaton Lambert paraneoplásico en el contexto de un carcinoma de pulmón de células pequeñas que trata de ilustrar esta cronología y abordar el proceso diagnóstico y terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Eaton Lambert syndrome is an autoimmune disorder that involves the neuromuscular junction. Clinical course includes proximal muscular weakness and symmetry. In 60% of cases this is associated with underlying neoplasia. Given that this weakness is of insidious onset, patients usually initially consult their family doctor. Recognizing this condition is essential for early diagnosis of oncological disease as it usually occurs a few months prior to local symptoms arising from tumour disease. The family doctor plays a crucial role in early diagnosis and should refer early to hospital to complete the study. We report a case study of paraneoplastic Eaton Lambert syndrome in the context of a small cell lung carcinoma that tries to depict this chronology, in addition to tackling the diagnostic and therapeutic process.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[síndrome miasténico de Lambert-Eaton]]></kwd>
<kwd lng="es"><![CDATA[carcinoma de pulmón de células pequeñas]]></kwd>
<kwd lng="es"><![CDATA[síndromes paraneoplásicos]]></kwd>
<kwd lng="es"><![CDATA[enfermedades de la unión neuromuscular]]></kwd>
<kwd lng="en"><![CDATA[Lambert-Eaton myasthenic syndrome]]></kwd>
<kwd lng="en"><![CDATA[neuromuscular junction diseases]]></kwd>
<kwd lng="en"><![CDATA[paraneoplastic syndromes]]></kwd>
<kwd lng="en"><![CDATA[small cell lung carcinoma]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kesner]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dimachkie]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Barohn]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lambert-Eaton myasthenic syndrome]]></article-title>
<source><![CDATA[Neurol Clin]]></source>
<year>2018</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>379-94</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meerbeeck]]></surname>
<given-names><![CDATA[JP van]]></given-names>
</name>
<name>
<surname><![CDATA[Fennell]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Ruysscher]]></surname>
<given-names><![CDATA[DKM de]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Small-cell lung cancer]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>378</volume>
<numero>9804</numero>
<issue>9804</issue>
<page-range>1741-55</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rojas-Marcos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protocolo diagnóstico de la debilidad muscular]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2019</year>
<volume>12</volume>
<numero>76</numero>
<issue>76</issue>
<page-range>4515-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wendt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eder]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Wölfel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lippmann]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rodloff]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Botulismus: Diagnostik und Therapie [Botulism: Diagnosis and Therapy]]]></article-title>
<source><![CDATA[Dtsch Med Wochenschr]]></source>
<year>2017</year>
<volume>142</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1304-12</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ivanovski]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Miralles]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lambert-Eaton Myasthenic syndrome: early diagnosis is key]]></article-title>
<source><![CDATA[Degener Neurol Neuromuscul Dis]]></source>
<year>2019</year>
<volume>9</volume>
<page-range>27-37</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Namdarian]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Longano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grummet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hovens]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paraneoplastic syndromes in prostate cancer]]></article-title>
<source><![CDATA[Nat Rev Urol]]></source>
<year>2010</year>
<volume>7</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>681-92</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Titulaer]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Verschuuren]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2011</year>
<volume>10</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1098-107</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schoser]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Eymard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Datt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mantegazza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lambert&#8211;Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2017</year>
<volume>264</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1854-63</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keogh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sedehizadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maddison]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment for Lambert-Eaton myasthenic syndrome]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2011</year>
<volume>2011</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
